Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) will present at the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025 at the Marriott Marquis Hotel in New York City. Mike Catelani, President and CFO, will deliver the presentation and be available for one-on-one meetings.
The conference features over 60 selected companies across multiple sectors and expects more than 500 institutional and high-net-worth investors. The event includes main-stage presentations, expert panels, curated one-on-one meetings, and networking sessions. A video recording of Anixa's presentation will be available after the conference on the company website.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ANIX gained 3.47%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.
The conference will showcase more than 60 carefully selected companies across technology, healthcare, consumer, mining, precious metals, and other high-growth sectors. Over 500 institutional and high-net-worth investors are expected to attend. The event will feature main-stage presentations, expert panels, curated one-on-one meetings, and extensive networking sessions, creating meaningful opportunities for dialogue between growth companies and the investment community.
For more information about the conference and registration details, please visit Spartan Capital Investor Conference 2025 Registration.
A video recording of the company presentation will be available after the conclusion of the conference on the Company's website at Anixa Biosciences Events.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, olon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-spartan-capital-securities-second-annual-investor-conference-302592178.html
SOURCE Anixa Biosciences, Inc.
FAQ
When will Anixa Biosciences (ANIX) present at the Spartan Capital investor conference?
Who will represent Anixa Biosciences (ANIX) at the November 3, 2025 conference?
Where is the Spartan Capital Securities Second Annual Investor Conference on November 3, 2025?
Will Anixa (ANIX) make the presentation available after the Spartan Capital conference?
How many investors and companies are expected at the Spartan Capital November 3, 2025 conference?
Can investors request one-on-one meetings with Anixa (ANIX) at the conference on November 3, 2025?
